Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
BMC Neurol ; 23(1): 319, 2023 Sep 07.
Article in English | MEDLINE | ID: mdl-37679689

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is a common cause of dementia. Serum complement factor 5a (C5a) is exceedingly implicated in AD. We explored the role of C5a levels in AD patients of different severity. METHODS: Mild, moderate, and severe AD patients, and healthy controls were included. C5a and pro-inflammatory factor (TNF-α, IL-1ß, IL-6, CRP) levels were assessed by ELISA, and cognitive function was evaluated by Mini-Mental state examination (MMSE) score. The correlations between C5a, inflammatory factor levels, MMSE score, and plasma Aß42/Aß40 ratio were analyzed by Pearson tests. Independent risk factors for AD aggravation were assessed by logistic multivariate regression analysis. According to the cut-off value of receiver operating characteristic (ROC) curve analysis of C5a level, AD patients were assigned into low/high expression groups, and severe AD incidence was compared. Severe AD cumulative incidence was analyzed by Kaplan-Meier curve. RESULTS: Serum C5a, TNF-α, IL-1ß, IL-6 and CRP levels were raised, and MMSE score was lowered in AD. Serum C5a, TNF-α, IL-1ß, IL-6 and CRP levels in severe AD patients were higher than those in mild/moderate AD patients, but there were no significant differences in these cytokines between moderate and mild AD groups. The MMSE score of severe AD patients was lower than that of mild/moderate AD patients. Serum C5a level was positively correlated with serum TNF-α, IL-1ß, IL-6, and CRP levels, and negatively correlated with MMSE score, with no obvious correlation with plasma Aß42/Aß40 ratio. Serum C5a level was one of the independent risk factors for AD aggravation. The occurrence of severe AD might be related to an increase in serum C5a level. CONCLUSION: Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function.


Subject(s)
Alzheimer Disease , Complement C5a , Humans , Alzheimer Disease/blood , Alzheimer Disease/pathology , Alzheimer Disease/psychology , Complement C5a/analysis , Inflammation/blood , Cognition , Male , Female , Aged , Patient Acuity
3.
Horm Metab Res ; 54(10): 704-710, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36055280

ABSTRACT

Ischemic stroke leads to high mortality and disability rates in humans. Cerebral ischemic injury has a severe complex pathophysiological mechanism. The abnormal release of inflammatory cytokines will cause brain tissue damage and destroy the blood-brain barrier integrity, which aggravates the process of brain injury. Therefore, attenuating the level of inflammatory response is critical for the therapy of cerebral ischemia injury. This study examined the rule of SIP treatment to support neuron protective effect after cerebral injury in an animal model of middle cerebral artery occlusion (MCAO). After ischemia/reperfusion, neurological function, neuroglia cells activation, infarction volume, brain water content, brain tissue apoptosis ratio, and inflammatory response were assessed, and quantitative PCR and western blot were also detected, respectively. Treatment of SIP ameliorated neurological dysfunction, brain infarction, brain edema, and brain cell apoptosis after MCAO operation. Overexpression SIP also suppressed pro-inflammatory cytokines release. Furthermore, the protective effect of SIP on brain injury occurs through reduced neuroglia cells activation through downregulation of the NF-κB pathway. In summary, the present work indicated that SIP prevents ischemic cerebral infarction-induced inflammation and apoptosis by blocking inflammasome activation via NF-κB signaling pathway. Those results suggest that SIP treatment is an attractive strategy for prevention of ischemic cerebral infarction.


Subject(s)
Brain Injuries , Brain Ischemia , Receptors, Steroid , Reperfusion Injury , Animals , Brain Injuries/complications , Brain Injuries/metabolism , Cytokines/metabolism , Humans , Infarction, Middle Cerebral Artery/complications , Infarction, Middle Cerebral Artery/metabolism , Inflammasomes , NF-kappa B/metabolism , Reperfusion Injury/etiology , Reperfusion Injury/metabolism , Reperfusion Injury/prevention & control , Water
4.
Endocr J ; 69(9): 1061-1065, 2022 Sep 28.
Article in English | MEDLINE | ID: mdl-35321983

ABSTRACT

This retrospective case-control study was designed to explore the association between the duration of diabetes and gram-negative bacterial infection in diabetic foot infections (DFIs). All DFI patients hospitalized in the Department of Endocrinology in the Sixth Affiliated Hospital of Sun Yat-sen University between 2013 and 2019 with positive microbial culture results were included. Cases were defined as DFI patients whose microbial cultures grew gram-negative bacteria (including polymicrobial flora). Controls were defined as DFI patients whose positive microbial cultures did not grow gram-negative bacteria. Clinical data were extracted from the hospital information system. Stabilized inverse probability weighting was used to balance between-group differences at baseline. Confounders were selected using a directed acyclic graph. Missing data were imputed with the multiple imputation of chained equations method. Odds ratios (ORs) with 95% confidence intervals (CIs) and Ptrend for associations between the duration of diabetes and gram-negative bacterial infection were obtained using binomial logistic regression models. The weighted OR of gram-negative bacterial infection for DFI patients with a moderate duration of diabetes (8~19 years) compared with those with a short duration (0~7 years) was 3.87 (95% CI: 1.15 to 13.07), and the OR for those with a longer duration (20~30 + years) was 7.70 (95% CI: 1.45 to 41.00), and there was a dose-response trend with increasing duration of diabetes (weighted Ptrend = 0.007). The results demonstrated that a long duration of diabetes might be associated with an increased risk of gram-negative bacterial infection in type 2 diabetes patients with DFI.


Subject(s)
Diabetes Mellitus, Type 2 , Diabetic Foot , Gram-Negative Bacterial Infections , Anti-Bacterial Agents/therapeutic use , Case-Control Studies , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Foot/epidemiology , Gram-Negative Bacterial Infections/complications , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Humans , Retrospective Studies
5.
Behav Neurosci ; 135(6): 721-731, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34096742

ABSTRACT

Emotional memory deficit is often accompanied by Alzheimer's disease and normal aging. It is important to do what is possible to alleviate or rescue emotional memory deficit in aging to improve the quality of older adults. Hesperetin is a flavonoid and an aglycone of hesperidin, it easily passes through the blood-brain barrier into the brain and exerts neuroprotective effects. However, little is known about its neuroprotective effect on emotional memory in aging. To address this issue, we examined the role of hesperetin in the regulation of hippocampal long-term potentiation (LTP), surface expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) including glutamate receptor 1 subunit-containing AMPAR (GluA1) and glutamate receptor 1 subunit-containing AMPAR (GluA2), malondialdehyde (MDA) concentration, reduced glutathione (GSH) concentration, and associative fear memory in aged rats. We found that aged rats exhibited impaired emotional memory and LTP. Furthermore, we also found oral administration of hesperetin ameliorated the impairment of emotional memory and LTP. Finally, we demonstrated hesperetin rescued impaired LTP possibly via enhancing AMPAR trafficking and oxidant-antioxidant balance in aged rats. These results imply a pivotal role for hesperetin in synaptic plasticity and associative fear memory in aged rats and suggest that hesperetin is a potential candidate for treating emotional memory deficit in aging. (PsycInfo Database Record (c) 2021 APA, all rights reserved).


Subject(s)
Hesperidin , Animals , Hesperidin/pharmacology , Hippocampus , Long-Term Potentiation , Neuronal Plasticity , Rats
6.
Acta Neurol Belg ; 121(6): 1415-1421, 2021 Dec.
Article in English | MEDLINE | ID: mdl-32036555

ABSTRACT

Intravenous injection of alteplase is recommended for patients with minor disabling and not non-disabling ischemic stroke symptoms within 4.5 h of ischemic stroke symptom onset. However, it is hard for clinicians to distinguish which type of minor ischemic stroke is disabled at an early stage. In this study, we aimed to demonstrate early neutrophil-to-lymphocyte ratio is a prognostic marker in acute minor stroke or transient ischemic attack. 196 patients diagnosed with acute minor stroke or transient ischemic attack within 24 h of symptom onset were enrolled. Patients were divided into three groups according to the neutrophil-to-lymphocyte ratio value (< 2, 2-3, > 3). Clinical, neuroradiological, laboratory and follow-up data were collected from electronic database. Functional outcome was assessed by modified Rankin Scale. Neutrophil-to-lymphocyte ratio associated with functional outcome of 90 days was evaluated by logistic regression analysis, and we used receiver operating characteristic curve analysis to detect the overall predictive accuracy of this marker. Early neutrophil-to-lymphocyte ratio was associated with an increased risk of short-term functional outcome (OR 4.502, 95% CI 1.533-13.046, P = 0.006). The optimal cutoff value of neutrophil-to-lymphocyte ratio for prediction of short-term unfavorable outcome was 2.94 with a sensitivity of 69.6% and a specificity of 77.1% (area under the curve: 0.767, 95% CI 0.691-0.843). Early neutrophil-to-lymphocyte ratio is associated with short-term unfavorable functional outcome in patients with acute minor stroke or transient ischemic attack. Early neutrophil-to-lymphocyte ratio is beneficial for clinicians to distinguish minor disabling ischemic stroke at an early stage.


Subject(s)
Brain Ischemia/blood , Ischemic Attack, Transient/blood , Lymphocytes/metabolism , Neutrophils/metabolism , Stroke/blood , Aged , Biomarkers/blood , Brain Ischemia/diagnostic imaging , Female , Follow-Up Studies , Humans , Ischemic Attack, Transient/diagnostic imaging , Male , Middle Aged , Prognosis , Retrospective Studies , Stroke/diagnostic imaging
7.
Curr Neurovasc Res ; 17(1): 86-92, 2020.
Article in English | MEDLINE | ID: mdl-31957613

ABSTRACT

BACKGROUND: Alzheimer's disease (AD) is the most common neurodegenerative disease, and the accumulation of amyloid-ß is the initial process in AD. MicroRNAs (miRNAs) are widely known as key regulators of the accumulation of amyloid-ß in AD. This study analyzed the potential effects and possible internal mechanisms of miR-340 on AD. METHODS: The expression of miR-340 in senescence-accelerated mouse prone-8 (SAMP8) mouse and senescence-accelerated mice/resistant-1 (SAMR1) mouse was evaluated by qRT-PCR (quantitative real-time polymerase chain reaction). The expression of ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) was determined by qRT-PCR and western blot. The binding ability between miR-340 and BACE1 was verified by dual-luciferase reporter assay. In vitro cell model of AD was established in human neuroblastoma SH-SY5Y cells transfected with Swedish mutant form of amyloid precursor protein (APPswe). The effect of miR-340 on the accumulation of amyloid- ß was investigated by western blot analysis. Flow cytometry was conducted to detect cell apoptosis. RESULTS: MiR-340 was down-regulated in the hippocampus of AD model SAMP8 mouse compared to SAMR1 mouse, while BACE1 was up-regulated in SAMP8, suggesting a negative correlation between miR-340 and BACE1 in SAMP8 mouse. MiR-340 could directly bind with BACE1, and over-expression of miR-340 decreased expression of BACE1 in SH-SY5Y/APPswe cells. MiR- 340 reduced the accumulation of amyloid-ß and suppressed cell apoptosis through targeting BACE1 in SH-SY5Y/APPswe cells. CONCLUSION: MiR-340 was downregulated in AD and reduced the accumulation of amyloid-ß through targeting BACE1, suggesting a potential therapeutic target for AD.


Subject(s)
Alzheimer Disease/metabolism , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Peptides/metabolism , Aspartic Acid Endopeptidases/metabolism , Hippocampus/metabolism , MicroRNAs/metabolism , Alzheimer Disease/genetics , Amyloid Precursor Protein Secretases/genetics , Animals , Aspartic Acid Endopeptidases/genetics , Cell Line , Cell Line, Tumor , Disease Models, Animal , Down-Regulation , Humans , Mice , MicroRNAs/genetics , Neurons/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...